The latest trial win won’t affect Enhertu’s regulatory status in the U.S. Back in 2021, the FDA approved Enhertu in stomach cancer following prior treatment with a trastuzumab (Herceptin ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi Sankyo over beast cancer drug Enhertu ... in damages isn't warranted "despite the ...

T-DM1 contains a boxed warning from the FDA. This is the strongest possible warning the FDA requires and indicates that a drug has a significant risk for serious or life threatening adverse effects.

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

In the overall trial population, the median progression-free survival was 13.2 months in patients randomized to Enhertu compared to 8.1 months in those randomized to chemotherapy See what stocks ...